Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen is transforming the treatment landscape for patients living with solid tumors,” said Kiran Patel, M.D., Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. “The data to be presented at ESMO represent Janssen’s commitment to push the boundaries of innovation on the path to redefine the treatment landscape for people with cancer.”Key highlights from Janssen-sponsored studies to be presented at ESMO include: Data Featuring RYBREVANT® as a Monotherapy and in Combination with Lazertinib in EGFR-Mutated NSCLC·Mini Oral Presentation: Preliminary results from the Phase 1b CHRYSALIS-2 study examines RYBREVANT® and lazertinib in patients with NSCLC and EGFR exon 19 deletion or L858R mutations (Abstract #1193MO)Mini Oral Presentation: Phase 1 CHRYSALIS study evaluates RYBREVANT® as a monotherapy and in combination w...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Abiraterone Acetate | Actos | Alcoholism | Alimta | Allergy & Immunology | Anemia | Arrhythmia | Bilirubin | Biotechnology | Bladder Cancer | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemistry | Chemotherapy | Child Development | Children | Clinical Trials | Congestive Heart Failure | Constipation | Corticosteroid Therapy | Cough | Dermatitis | Dermatology | Diabetes | Drugs & Pharmacology | Endocrinology | Epilepsy | Epithelial Cancer | Fallopian Tube Cancer | Food and Drug Administration (FDA) | Gastroschisis Repair | Headache | Health Management | Heart | Heart Attack | Heart Disease | Heart Failure | Hematology | Hepatitis | Hepatitis Vaccine | Hormones | Hypertension | Hypothyroidism | Infectious Diseases | Interstitial Lung Disease | Ischemic Stroke | Japan Health | Ketoconazole | Laboratory Medicine | Learning | Legislation | Liver | Lung Cancer | Marketing | Migraine | Myeloma | Neurology | Neuroscience | Non-Small Cell Lung Cancer | Opthalmology | Oral Cancer | Organic | Orthopaedics | Ovarian Cancer | Ovaries | Pain | Pain Management | Peritoneal Cancer | Pharmaceuticals | Pneomococcal Vaccine | Politics | Potassium | Prednisolone | Prednisone | Pregnancy | Pregnancy and Breast Cancer | Profits and Losses | Prostate Cancer | Pulmonary Hypertension | Respiratory Medicine | Science | Skin | Sodium | Stroke | Study | Thyroid | Thyroid Cancer | Toxicology | Universities & Medical Training | Urology & Nephrology | Vaccines | Ventricular Arrhythmia | Veterinary Vaccinations | Warnings